Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Technical Presentation (February 2021)
14 slides from Matinas Biopharma's technical presentation, Feb 1, 2021
Slide 1: ENHANCE-IT Topline Data Announcement
MATINAS ~ BIOPHARMA ENHANCE-IT Topline Data Announcement February 1, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Call Agenda
CALL AGENDA Opening Remarks — Jerome D. Jabbour, CEO Review of Results — James J. “Terry” Ferguson, M.D., FACC, FAHA - CMO . KOL Perspective — John Kastelein, M.D., Ph.D., FESC . Summary & Conclusions . Question & Answer Session MATINAS BIOPHARMA
Slide 4: Topline Data — Opening Remarks
ENHANCE-IT Topline Data — Opening Remarks Jerome D. Jabbour Chief Executive Officer 4 MATINAS BIOPHARMA,
Slide 5: LYPDISO — Formulated to Achieve Best-in-Class Potency
LYPDISO™ — Formulated to Achieve Best-in-Class Potency Less Bioavailable Highly Bioavailable ETHYL ESTHERS ee FREE FATTY ACIDS ~ LOVAZA* Vascepa’* Epanova'}’ Lyppiso™ DPA OTHER e 1ST GENERATION ° @— 2%° GENERATION —® Repurposed Products For CV Applications “estimated composition MATINAS BIOPHARMA
Slide 6: James J. "Terry" Ferguson, M.D., FACC, FAHA
James J. “Terry” Ferguson, M.D., FACC, FAHA Chief Medical Officer MATINAS BIOPHARMA
Slide 7: Study: LYPDISO vs Vascepa
ENHANCE-IT Study: LYPDISO™ vs Vascepa® OBJECTIVES To assess pharmacodynamic (PD) effects of LYPDISO™, compared with Vascepa’, on TGs and other lipoprotein lipids, apolipoproteins, hs-CRP, and PCSK9 in men and women with elevated TGs = Randomized, open-label, active-control crossover design (n=100) =
Slide 8: Plasma Fatty Acids — Pharmacodynamic (PD) Population
ENHANCE-IT — Plasma Fatty Acids — Pharmacodynamic (PD) Population PD Population (n=94) Fatty Acid EPA (ug/ml) DPA (ug/ml) DHA (ug/mt) EPA+DPA+DHA (nmol/mL ) Baseline End-of-Treatment % A from Baseline (Median) (Median) (Median) Relative % Increase in Omega-3 level A vs. Vascepa Lyppiso™ Vascepa® =~
Slide 9: EPA Blood Levels Were the Only Biomarker That Predicted CV Outcomes in REDUCE-IT
EPA Blood Levels Were the Only Biomarker That Predicted CV Outcomes in REDUCE-IT Primary Endpoints in REDUCE-IT as a Function of EPA Levels Relationship of EPA Levels to Outcome (HR) Primary Endpoint Key Secondary Endpoint 037 —— Placebo a i _ — lcosapent Ethyl EPA <116.9 g/mL pes ae = = Icosapent E
Slide 10: Lipoproteins and Inflammatory Markers - Pharmacodynamic (PD) Population
ENHANCE-IT — Lipoproteins and Inflammatory Markers- Pharmacodynamic (PD) Population PD Populati Variable* Median % A Lyppiso™ Vascepa® TG -21.9 - 15.7 0.27 1G =5.2 = 2s) 0.17 LDL-C sat = aes 0.24 VLDL-C - 16.3 = 12:9 0.26 HDL-C > 13 = es) 0.69 Non-HDL-C —7.5) -3.8 0.19 Apo Al -5.0 13:5) 0.46 Apo B -
Slide 11: Lipoproteins and Inflammatory Markers - Per Protocol (PP) Population
ENHANCE-IT — Lipoproteins and Inflammatory Markers- Per Protocol (PP) Population PP Population (N Variable** Median % A Lyppiso™ Vascepa® TG - 20.9* -13.8 0.04 1G =5.5% -2.3 0.04 IDE =5.6) eo 0.17 VLDL-C - 16.0* - 10.9 0.03 HDL-C -16 -2.0 0.52 Non-HDL-C =7.6 =3.2 0.07 Apo Al -5.0 ong) 0.44 ApoB S47
Slide 12: Topline Data — Key Opinion Leader Perspective
ENHANCE-IT Topline Data — Key Opinion Leader Perspective John Kastelein, M.D., Ph.D., FESC John is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascula
Slide 13: Summary and Conclusions
ENHANCE-IT — Summary and Conclusions > Plasma EPA concentrations were significantly higher with LYPDISO™, (46% relative percent increase change from baseline EPA level vs. Vascepa®) > Levels of EPA have been directly correlated with improvements in cardiovascular outcomes (Vascepa® in REDUCE-IT) > T
Slide 14: ENHANCE-IT Topline Data Announcement
MATINAS BIOPHARMA ENHANCE-/T Topline Data Announcement February 1, 2021
Matinas BioPharma Holdings — Technical Presentation (February 2021) on 6ix